Table 4.
Methodology of included models
| Study | Treatment -switching adjustment | Use of RWD for survival extrapolation or validation | Source for treatment duration | Use of 2-year stopping rule for treatment duration | Treatment-effect waning | Approach to utility modeling |
|---|---|---|---|---|---|---|
| Aggarwal et al. [28] | No/NR | No | NR | No/NR | NR | NR |
| Aggarwal et al. [29] | No/NR | No | NR | No/NR | NR | NR |
| Chouaid et al. [10] | No/NR | No | PFS | No/NR | NR | State based |
| Chouaid et al. [30] | No/NR | No | NR | No/NR | NR | NR |
| Criss et al. [11] | No/NR | Yes (extrapolation) | NR | No/NR | Base case | TTD |
| Georgieva et al. [31] | No/NR | No | NR | No/NR | NR | NR |
| Georgieva et al. [13] | No/NR | No | PFS | No/NR | NR | State based |
| Giuliani and Bonetti [14] | No/NR | No | NR | No/NR | NR | NR |
| Guirgis [32] | No/NR | No | NR | No/NR | NR | NR |
| Hu and Goldman [36] | No/NR | No | NR | No/NR | NR | NR |
| Hu and Hay [15] | No/NR | No | PFS | Yes | NR | State based |
| Hu X et al. [35] | No/NR | No | NR | No/NR | NR | State based |
| Huang et al. [17] | Scenario | Yes (extrapolation and validation) | Time on treatment | Yes | Base case | State based or TTD |
| Insinga et al. [18] | No/NR | Yes (extrapolation) | Time on treatment | Yes | Base case | TTD |
| Insinga et al. [19] | No/NR | Yes (extrapolation) | Time on treatment | Yes | Base case | TTD |
| Kim et al. [37] | No/NR | No | NR | No/NR | NR | NR |
| Liao et al. [20] | No/NR | No | PFS | Yes | NR | State based |
| NICE TA 531 [42] | Base case | No | Time on treatment | Yes | Scenario | State based or TTD |
| NICE TA 557 [41] | No/NR | No | Time on treatment | No/NR | Scenario | State based or TTD |
| NICE TA 584 [44] | No/NR | No | Time on treatment | No/NR | Base case | State based or TTD |
| NICE TA 600 [43] | No/NR | Yes (extrapolation) | Time on treatment | Yes | Scenario | State based or TTD |
| PBAC 6.01 [48] | No/NR | No | Time on treatment | No/NR | NR | State based |
| PBAC 6.04 [45] and resubmissions: 7.17 and 3.01 [47] | Base case | No | Time on treatment | Yes | Scenario | State based or TTD |
| PBAC 7.09 [49] | No/NR | No | Time on treatment | No/NR | NR | State based |
| pCODR 10101 [50] | Scenario | Yes (extrapolation) | NR | No/NR | Base case | State based |
| pCODR 10153 [51] | Economic guidance panel | No | Time on treatment | No/NR | Scenario | State based or TTD |
| Pinheiro et al. [38] | Base case | No | NR | No/NR | NR | TTD |
| Roth et al. [39] | No/NR | No | NR | No/NR | NR | NR |
| She et al. [22] | No/NR | No | PFS | Yes | NR | State based |
| SMC 1239/17 [53] | Base case | No | NR | Yes | Scenario | State based or TTD |
| SMC 2127 [54] and resubmission: SMC 2207 [52] | No/NR | No | PFS | Yes | Scenario | State based or TTD |
| SMC 2187 [55] | No/NR | Yes (extrapolation) | Time on treatment | No/NR | Scenario | State based or TTD |
| Tan et al. [40] | No/NR | No | NR | Yes | NR | State based |
| Wan et al. [24] | No/NR | No | PFS | Scenario | NR | State based |
| Wan et al. [23] | No/NR | No | NR | Unclear | NR | State based |
| Weng et al. [25] | No/NR | No | PFS | Yes | NR | State based |
| Zeng et al. [26] | No/NR | No | NR | No/NR | NR | State based |
| Zhou et al. [27] | No/NR | No | NR | No/NR | NR | State based |
For TAs with resubmission, the information presented represents the latest resubmission.
NICE National Institute for Health and Care Excellence, NR not reported, PBAC Pharmaceutical Benefits Advisory Committee, pCODR pan-Canadian Oncology Drug Review, PFS progression-free survival, RWD real-world data, SMC Scottish Medicines Consortium, TA technology appraisal, TTD time to death